Overview of Augmentin 625

Property	Description
Active Ingredients	Amoxicillin and Clavulanic Acid
Form	Film-Coated Tablet
Pharmacological Class	Penicillin-class Antibiotic with \beta-lactamase Inhibitor
General Purpose	To combat susceptible bacterial infections
Origin	Semi-synthetic (combination product)

What Type of Drug is Augmentin 625? (Classification and Origin)

Augmentin 625 is a prescription-only pharmaceutical preparation known by the generic designation Co-amoxiclav, which identifies it as a combined antibiotic and anti-infective agent. It belongs to the \beta-lactam class, specifically acting as a combination of a penicillin-class antibacterial and a \beta-lactamase inhibitor. The primary component, Amoxicillin, is a semi-synthetic derivative of the penicillin family. The secondary component, Clavulanic Acid (supplied as Potassium Clavulanate), is produced through fermentation. This formulation is clinically recognized for its systemic delivery via oral administration as a film-coated tablet. The formulation of Co-amoxiclav is shared among several manufacturers globally, making Augmentin a widely recognized reference brand for this specific \beta-lactam/inhibitor pairing.

Composition: Why Does Augmentin 625 Have Two Active Ingredients? (Composition and Form)

The two essential active ingredients are Amoxicillin trihydrate and Clavulanic Acid. The "625" in the name represents the total active ingredient weight per tablet. Amoxicillin's purpose is bactericidal action by disrupting the bacterial cell wall synthesis, whereas Clavulanic Acid functions as a potent \beta-lactamase inhibitor, binding to and inactivating the defensive enzymes that certain resistant bacteria produce. The design of this combination ensures reliable antibacterial performance even in scenarios where resistance to Amoxicillin alone is a factor.

What is the General Purpose of This Combination Antibiotic? (General Benefit)

The overall purpose is to achieve the effective elimination of susceptible bacteria from the body, leading to the resolution of bacterial infections. By shielding the Amoxicillin, the Clavulanic Acid component extends the antibacterial spectrum to include many strains that are normally resistant to non-potentiated penicillins. This specific combination is categorized as an essential medicine due to its utility in overcoming common bacterial resistance.

Regulatory References

What side effects are possible with Augmentin 625?

Possible Side Effects and Safety Information

The adverse reactions and safety profile for Augmentin 625 (Co-amoxiclav) are categorized by frequency and grouped according to the physiological system affected, based on official government regulatory documents.

Officially Documented Adverse Reactions

The most frequently reported side effects are categorized as follows:

Very Common (Affecting 1 in 10 or more people): Diarrhoea, particularly in adults.
Common (Affecting up to 1 in 10 people): Nausea, Vomiting, and Mucocutaneous candidiasis (thrush).
Uncommon (Affecting up to 1 in 100 people): Skin rash, Urticaria (hives), Indigestion, Headache, and Dizziness. Uncommon effects also include a moderate rise in liver enzyme levels (AST and/or ALT).

Other less frequent reactions (rare and very rare) are also officially documented, including reversible blood cell changes (leucopenia, thrombocytopenia) and a severe rash known as erythema multiforme.

Serious Adverse Reactions and Systemic Concerns

Certain reactions, though rare, are considered serious and are highlighted in official labeling:

Hypersensitivity: Severe, immediate allergic reactions, including anaphylaxis and angioedema, are known to occur.
Hepatobiliary Disorders: Very rare events include hepatitis and cholestatic jaundice. These hepatic events may appear during or shortly after treatment but can also be delayed, manifesting several weeks after treatment has ceased.
Gastrointestinal: Serious reactions include antibiotic-associated colitis.

Safety Constraints and Considerations

The medicine is formally contraindicated in individuals with a known history of hypersensitivity to penicillin or other beta-lactam antibiotics. It is also contraindicated in patients with a history of jaundice or hepatic dysfunction specifically related to previous Co-amoxiclav use. Regulatory information notes that nausea is often associated with higher oral dosages. Furthermore, convulsions have been reported, particularly in individuals with impaired kidney function.

Overdose and Emergency Response

Documented Overdose Manifestations

The official regulatory documents state that an overdose of Amoxicillin and Clavulanate Potassium primarily affects the gastrointestinal and renal systems. Documented manifestations commonly include nausea, vomiting, stomach pain, and diarrhea, which can sometimes lead to a disturbance of the fluid and electrolyte balances. Neurological symptoms, such as drowsiness and reversible hyperactivity, have also been reported in official labeling.

Severe Outcomes and Help-Seeking Requirements

A severe outcome associated with overdose is the potential development of Amoxicillin crystalluria, which may manifest as decreased urination and could potentially lead to renal failure. The official prescribing information notes that convulsions (seizures) may occur, particularly in patients with pre-existing impaired renal function or following the ingestion of exceptionally high doses.

Since no specific antidote is known, the regulatory standard mandates that the drug must be discontinued and management is symptomatic and supportive. The required action is to seek emergency medical attention immediately or contact emergency services if an overdose is suspected or if severe symptoms, like convulsions, are present. Hemodialysis is documented as a procedural measure that can effectively remove the drug components from the circulation.

Therapeutic Uses of Augmentin 625

What Augmentin 625 Treats: Main Uses and Benefits

Augmentin 625 (Co-amoxiclav) is a combination antibiotic that is commonly applied to help manage bacterial infections across several organ systems, and is relevant in contexts where resistance to similar treatments is a factor. It is commonly used in settings marked by increased discomfort or tension and acute symptomatic episodes.

This medication is generally considered relevant for conditions characterized by periods of heightened symptoms in the respiratory tract (e.g., acute bacterial sinusitis, exacerbations of chronic bronchitis), the urogenital system (e.g., pyelonephritis), skin and soft tissues (e.g., cellulitis and abscesses), and in some bone and joint infections.

The therapeutic benefit generally relates to addressing symptoms that create noticeable physiological strain, as the medication is used across domains where additional symptomatic support is needed. It is relevant for easing symptom clusters that may become intense, such as fever, cough, and localized pain, and provides support that helps maintain a sense of stability when symptoms are more noticeable.

“It is commonly used across conditions presenting with acute episodes and is applied when symptoms create noticeable functional strain.”

Quick Fact: Relief for Localized Inflammatory Pain

Augmentin 625 may be part of symptomatic management in situations involving localized pain, swelling, and redness, such as deep skin infections or dental abscesses, and provides supportive relief when symptoms interfere with routine activities.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Augmentin 625 (amoxicillin/clavulanate potassium) is prescribed for adults and children weighing 40 kg or more to treat various bacterial infections, including those of the respiratory tract, urinary tract, and skin. Dosage for children under 40 kg or under 12 years of age is determined by their weight and is typically administered using a suspension formulation.

Contraindications and Warnings

Augmentin 625 is not suitable for all patients. You must not take this medication if you have a history of:

Allergy to penicillin, cephalosporin antibiotics, amoxicillin, clavulanate, or any other ingredients in Augmentin.
Liver problems or jaundice (yellowing of the skin or eyes) previously associated with taking Augmentin or any amoxicillin/clavulanate product.
Severe kidney disease (severe renal impairment).

Special Precautions

Inform your healthcare provider if you have kidney disease (as dose adjustment may be necessary), liver problems, or infectious mononucleosis (glandular fever), as these conditions may increase the risk of certain side effects. Use during pregnancy and breastfeeding should be discussed with a doctor, who will weigh the potential risks and benefits. Augmentin may also reduce the effectiveness of oral contraceptives (birth control pills).

What should I know about interactions with other medicines?

Augmentin 625 (Amoxicillin/Clavulanate) exhibits officially documented interaction patterns that are classified based on pharmacokinetic changes, pharmacodynamic effects, and risk modification.

Drug-Drug Interactions

The drug Probenecid is noted to decrease the renal tubular secretion of the Amoxicillin component, resulting in a documented increase and prolongation of Amoxicillin's plasma concentration. Concomitant use with Methotrexate may reduce the latter's excretion, potentially leading to increased systemic exposure and a risk of toxicity. Co-administration with Allopurinol is stated in regulatory labeling to increase the reported incidence of allergic skin rash compared to Amoxicillin use alone.

Pharmacodynamic and Conditional Risks

Pharmacodynamic interactions involve Oral Anticoagulants; concurrent use may lead to a reported increase in International Normalized Ratio (INR) and prolongation of prothrombin time, which requires close attention. Use with Combined Oral Contraceptives may lead to reduced hormonal efficacy due to effects on intestinal flora. The combination is conditionally contraindicated with anti-peristaltic agents if the patient develops antibiotic-associated colitis.

Population and Food Considerations

The clearance of the Amoxicillin component is primarily renal, meaning severe renal impairment may result in slower drug elimination and increased systemic exposure. For optimal absorption, regulatory documents state that the absorption of the Clavulanate component is greater when the medicine is administered with a meal. Use is avoided in patients with infectious mononucleosis due to the increased risk of skin rash.

Mechanism of Action

Directly Shutting Down Bacterial Cell Wall Assembly

The component Amoxicillin acts as an irreversible inhibitor of crucial bacterial enzymes called Penicillin-Binding Proteins (PBPs), which are responsible for the final cross-linking of the peptidoglycan layer. By blocking this step, the drug initiates a cascade: the cell wall structure is compromised, leading to the physical rupture (lysis) of the bacterial cell due to internal osmotic pressure. This molecular interference underlies the drug's core cell-killing function.

Mechanistic Protection Against beta-Lactamase Defense

The second component, Clavulanic Acid, is a suicide inhibitor that specifically targets and irreversibly deactivates beta-lactamase enzymes produced by resistant bacteria. These enzymes would otherwise destroy Amoxicillin, rendering it inert. The acid's function is purely mechanistic: by neutralizing the defense enzymes, it protects Amoxicillin from hydrolysis, enabling it to access the PBPs and complete the cell wall-disrupting cascade. This strategy supports the maintenance of the bactericidal effect against certain strains of resistant bacteria.

Dosage and Administration Information

Augmentin 625 mg (Amoxicillin 500 mg/ Clavulanic Acid 125 mg) is administered exclusively by the oral route as a film-coated tablet. This combination is typically designated for short-term use, and the full course of treatment should not be extended beyond 14 days without a medical review.

Standard Labeled Dosing Regimens

For adults and pediatric patients weighing 40 kg or more, dosing follows regimens based on the required total daily amoxicillin dose. For less severe infections, the standard regimen is one 500 mg/ 125mg tablet taken every 12 hours (twice daily). For more severe infections or those involving the respiratory tract, the dose may be increased to one 500 mg/ 125mg tablet taken every 8 hours (three times daily).

Administration Context and Instructions

Administration must occur at the start of a meal to ensure the optimal absorption of the clavulanate component and to minimize potential gastrointestinal intolerance. The tablet should be swallowed whole. Although some tablets feature a score line, product specifications indicate this is only to facilitate easier swallowing and not for the purpose of dividing the dose.

Population-Specific Use

Dosing is adjusted based on specific requirements for patients with reduced renal function. For individuals with moderate renal impairment (creatinine clearance 10 -30 mL/ min), the dose is typically one 500 mg/ 125mg tablet twice daily. For severe impairment (creatinine clearance < 10 mL/ min), the frequency is reduced to once daily. Generally, no dose adjustment is considered necessary for older adults or pediatric patients weighing 40 kg.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Amoxicillin-Clavulanate

The clinical research on this medication involves various studies, including Randomized Controlled Trials (RCTs) and systematic reviews, which analyze findings from many individual studies. The goal of this research is to explore how symptoms change over time and to monitor research findings across conditions characterized by acute or disruptive episodes.

Evidence for Use in Respiratory Tract Infections (Ear, Sinus, and Lung)

Research explored the study of this medication in populations with acute bacterial sinusitis, acute otitis media (ear infection), and community-acquired pneumonia (lung infection). These studies monitored outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level.

For instance, in sinusitis trials, researchers monitored measured change in symptoms over defined time intervals. Studies monitored how measured clinical endpoints evolved in cohorts involving bacteria that produce beta-lactamase enzymes. However, comparative evidence is lacking to definitively establish superior clinical outcomes when comparing this combination to amoxicillin alone in cases where the presence of a resistant organism was not confirmed. Some reviews reported a lack of substantial difference in clinical outcomes when comparing this combination to other studied interventions.

Evidence in Specific Patient Populations and Research Gaps

Research includes studies where this medication was evaluated in specific patient groups, such as pediatric populations (children) and older adults. For children, studies are ongoing to better understand drug exposure levels across all age ranges. For older adults, studies examined comparative patterns against other interventions, but data for certain groups remain insufficient in many areas, as the primary effectiveness studies were designed for the general patient population.

Long-term effects are not fully established regarding durability of response or potential for infection recurrence over many months, as follow-up durations were limited in many of the key effectiveness trials. The collective evidence provides context, but research does not determine whether an individual will respond similarly to the patients included in the trials. Research is ongoing to explore these gaps, particularly concerning the drug's exposure levels and long-term outcomes.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Augmentin 625 (FAQ)

Q: Does Augmentin 625 affect birth control pills?

Official prescribing information indicates that co-administration with combined oral contraceptives may lead to reduced hormonal efficacy. This is due to potential effects on the intestinal flora, which can interfere with how the body handles the hormones. Official information recommends that patients using oral contraceptives discuss the need for additional protective measures with a healthcare professional.

Q: Can Augmentin 625 be taken with pain relievers like ibuprofen?

Regulatory documents typically do not list a specific direct interaction between amoxicillin/clavulanate and non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. This means there is no common, well-documented drug-drug interaction for this specific combination in official information.

Q: What are the signs of a severe allergic reaction to Augmentin 625?

Signs of a severe, immediate allergic reaction listed in official information may include breathing difficulties, wheezing, or swelling of the face, lips, or throat. Severe skin reactions such as extensive rash, blistering, or peeling of the skin are also documented, and these are considered serious events.

Q: What type of research supports the safety profile of Augmentin 625?

The safety profile of the medicine is informed by clinical trials conducted before approval. Furthermore, the safety profile is continually monitored through official post-marketing surveillance, which tracks reported adverse events after the medicine is widely used by the public.

Q: Can older adults use Augmentin 625 without special concerns?

Official information notes that generally no dose adjustment is necessary for older adults based on age alone. However, the documentation notes that rare hepatic (liver-related) events have been reported to occur predominantly in elderly patients.

Q: What happens if Augmentin 625 is stopped before the course is finished?

Patient information states that stopping the full course of medicine early, even if symptoms begin to improve, may risk the infection returning. This increases the potential for the bacteria to develop resistance to the treatment. Regulatory patient information indicates the importance of completing the full prescribed course.

Q: Can children or adolescents use Augmentin 625?

The tablet formulation is typically recommended for adolescents and children who weigh 40 kilograms or more, as the dosing for this group aligns with adult recommendations. For children weighing less than 40 kilograms, different formulations, such as an oral suspension, are generally used for accurate dosing.

Q: Does Augmentin 625 affect liver function in healthy people?

Official documentation lists a moderate rise in liver enzyme levels (AST and/or ALT) as an uncommon effect. In rare cases, more serious hepatic events, such as hepatitis or cholestatic jaundice (a type of liver-related yellowing), are also documented in the official safety profile.

Q: What is the difference between Augmentin 625 and other antibiotic strengths like 375mg or 1000mg?

The difference between strengths is the specific amount and ratio of the two active ingredients (amoxicillin and clavulanic acid). The 625 mg tablet contains 500 mg of amoxicillin. Because the ratios change across products, regulatory information advises that two lower-strength tablets are generally not equivalent or interchangeable with one higher-strength tablet.

Q: Is Augmentin 625 effective against viral infections?

Official regulatory warnings state that this medicine is an antibacterial agent, meaning it is only designed to eliminate susceptible bacteria. It is not effective for treating infections caused by viruses, such as the common cold or the flu.

Q: What does 'antibiotic resistance' mean in relation to Augmentin 625?

Antibiotic resistance is when bacteria develop the ability to overcome the drug's effect, making the medicine less successful in treating the infection. The clavulanic acid component is included specifically to help overcome a common form of bacterial resistance that occurs when bacteria produce protective enzymes.

Q: Can Augmentin 625 affect the results of blood tests?

Official information notes that this medication may affect the results of some laboratory tests. This includes tests checking for glucose (sugar) in the urine, and may also involve temporary, reversible changes in blood cell counts or liver enzyme levels.

Q: What kind of infections is Augmentin 625 typically reserved for?

The combination with clavulanic acid is generally used for bacterial infections, including those that are known or suspected to be caused by bacteria that are resistant to amoxicillin alone. The clavulanic acid component is specifically included to target bacteria with that particular defense mechanism.

Q: Is there scientific data available on how well Augmentin 625 works for specific bacterial strains?

Official regulatory information includes a listing of specific bacterial organisms. This list outlines the particular strains that are usually susceptible to the amoxicillin/clavulanic acid combination, which is based on laboratory data and clinical research.

Q: Is it true that Augmentin 625 can cause tendon issues?

Tendon issues (such as tendinitis or rupture) are not commonly listed as an adverse reaction associated with this specific class of antibiotics (penicillins) in official documentation. This type of effect is typically linked to a different class of antibacterial medicines.

Q: How can you tell if Augmentin 625 is actually working for the infection?

Official patient information advises completing the full course of medicine as prescribed. The information also recommends contacting a healthcare professional if symptoms are not improving after completing the full course, or if the patient feels worse at any time during the treatment.

Q: Is the medication designed to fight a broad range of bacteria?

The addition of clavulanic acid is designed to extend the antibacterial spectrum of amoxicillin. This combination is intended to be effective against a wider range of bacteria, including those that produce certain protective enzymes, making it a broader-spectrum agent than amoxicillin alone.

Q: What should be done if a dose of Augmentin 625 is missed?

If a dose is missed, regulatory patient information advises taking it as soon as it is remembered. The information emphasizes the need to then continue with the regular schedule. The information also advises against taking two doses at the same time or extra doses to make up for the missed one.

Q: Does taking Augmentin 625 require avoiding any specific foods or drinks?

Regulatory patient information advises that the medicine should be taken with a meal to minimize the possibility of gastrointestinal upset. Additionally, some authoritative patient materials recommend avoiding the consumption of alcohol during and for several days after treatment.

Q: Why might a doctor prescribe Augmentin 625 instead of another type of antibiotic?

Official documents note that the clavulanic acid component protects the amoxicillin from being inactivated by bacterial enzymes (beta-lactamases). This protection is often the reason this combination is selected when an infection is known or suspected to involve bacteria with this type of resistance.

Q: Are there any known interactions between Augmentin 625 and alcohol?

Some authoritative patient information materials advise avoiding alcohol during and for several days after treatment. Although there is no widely listed pharmacological interaction that creates a direct severe risk, alcohol may potentially increase the risk of certain side effects like nausea or liver-related issues.

How should Augmentin 625 be stored and disposed of?

How to Store and Dispose of Augmentin 625 mg Tablets

The storage and disposal of Augmentin 625 mg tablets are governed by official regulatory instructions to ensure product stability and safety.

Official Storage Requirements

The tablets must be stored in the original container to maintain protection from moisture and must not be stored above 25 C or 30 C, depending on the specific product labeling. The medication must be kept in a dry place.

Storage Constraint	Requirement
Temperature Limit	Do not store above 25 C or 30 C.
Container Rule	Store in the original package.
Protection	Protect from moisture; Store in a dry place.

Stability and Disposal

For tablets supplied in Desiccated Pouch Packs (DPP), the product must be used within 30 days of opening the outer packaging. Augmentin 625 must be kept out of the sight and reach of children.

Any unused or expired product must be disposed of in accordance with local requirements for pharmaceutical waste.

Augmentin 625